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ABSTRACT
Objectives To determine if there is an association
between acuity level of care (ALC), case fatality and length
of stay in patients admitted to hospital due to COVID-19.
Design A hospital-based observational follow-up study.
Setting Internal Medicine Service of the Aga Khan
University Hospital, Pakistan, from 26 February 2020 to 30
June 2020.
Participants Adult patients with confirmed COVID-19,
aged ≥18 years.
Methods ALC was categorised into low, intermediate
and high level and patients were triaged using the
standard emergency severity illness score. All patients
were followed until the end of hospital admission for the
outcome of case fatality and length of stay.
Results A total of 822 patients with COVID-19 were
admitted during the study period and 699 met inclusion
criteria. The mean age was 54.5 years and 67% were
males; 50.4% were triaged to low, 42.5% to intermediate
and 7.2% to high acuity care. The overall case-fatality rate
was 11.6%, with the highest (52%) in high acuity level
followed by 16.2% in intermediate and 2% in low acuity
care. Acuity level was associated with case fatality, with an
HR (95% CI) of 5.0 (2.0 to 12.1) for high versus low acuity
care and an HR of 2.7 (1.2, 6.4) for intermediate versus
low acuity care, after adjusting for age, sex and common
comorbidities including diabetes, hypertension, ischaemic
heart disease and chronic lung disease. Similarly, acuity
level was also associated with length of hospital stay.
Conclusion High and intermediate acuity level is
associated with higher case fatality rate and prolonged
length of hospital stay in patients admitted with COVID-19.
In resource-limited settings where the provision of high
acuity care is limited, the intermediate care acuity could
serve as a useful strategy to treat relatively less critical
patients with COVID-19.
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INTRODUCTION
COVID-19 is caused by SARS-CoV-2, the novel
coronavirus, which rapidly converted into a
pandemic causing global concern.1–3 More
than 26 million cases were reported until 9
September 2020, of which 871 166 died.4

Strengths and limitations of this study
►► This study determines the link between acuity level

of care and case fatality and length of stay in patients with COVID-19 in a lower–middle-
income
country.
►► This observational follow-up study and data extracted from medical records reduce possible recall bias
and selection bias.
►► It is a single-centre hospital-based study and cannot be generalised to the fatality rates in the general
population.
►► Clinical and laboratory details of patients are not reported in detail in this study.

Preparing to combat this pandemic is more
challenging for low-
income and middle-
income countries (LMICs) such as Pakistan
with a population of over 212 million and
a total health expenditure of only 2.6% of
the gross domestic product. The first case
of COVID-19 was reported in Karachi on 26
February 2020, and although population-
based screening for COVID-19 was not
done, 298 509 cases had been reported with
an overall mortality of 2.5%.5 Availability of
critical care units and trained healthcare
staff for managing patients with COVID-19
due to limited resources is a major challenge
for hospitals in Pakistan. Due to this limitation, some critical patients are admitted to
intermediate care units instead, who do not
require urgent invasive ventilation. However,
the outcome of these COVID-19 patients in
terms of fatality or progression of the infection has not been reported thus far.
Acuity level of care (ALC) to patients is
defined as an attribute of severity, intensity paired with patient, provider or system,
according to Holzemer’s Outcomes Model
for Health Care Research.6 Besides, it also
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encompasses physical, psychological and nursing care
needs, workload and complexity, urgency and triage scales.
ALC level in healthcare is linked with patients’ safety and
mortality.7 8 An adequate number of beds with the right
level of acuity to manage potentially critical patients with
COVID-19 is therefore crucial to decrease suffering and
avoid high mortality. However, whether the level of acuity,
more specifically of intermediate care units, is linked
to a favourable or less favourable outcome in patients
with COVID-19 is not well known and especially not in
LMIC. The WHO reports that 80% of those infected by
SARS-CoV-2 develop mild symptoms, 14% have severe
symptoms and 6% will complicate into a critical disease.9
In a crisis situation such as the COVID-19 pandemic,
institutional-based algorithms can aid clinicians to triage
patients more efficiently.10 Due to the acute shortage of
ventilators that many LMICs are facing, the decision to
admit patients to high acuity becomes difficult.11 Also, in
such LMICs triaging and admitting to the correct level
of care is not only important for patient outcomes but
also helps in prioritising healthcare resources efficiently.
In general, patients triaged as having a higher ALC
require a greater number of emergency or admitting
service resources.12 Hence, ALC is an indirect measure
of the severity of illness of patients and required healthcare resources to manage them. Illness severity scores
are linked to the acuity of hospital settings.13 Five‐level
systems such as the Emergency Severity Index (ESI) and
the Canadian Triage Acuity System are considered more
reliable than three‐level systems and are commonly used
to triage based on the severity of illness and acuity.14 15
The Centers for Disease Control(CDC) and Prevention,
USA, categorises patients with COVID-19 requiring hospitalisation into three levels of patient acuity.16 Non-acute
care means general, low‐level care for mild-to-moderately
symptomatic patients who may require oxygen (less than
or equal to 2 L/min) but does not require extensive
nursing care; mid-level care for moderately symptomatic
patients means patients who require high oxygen support
(more than 2 L/min), nursing care and assistance with
activities of daily living and high acuity care for patients
means patients who require significant ventilatory
support, including intensive monitoring. Case fatality or
length of hospital stay concerning the three ALC has not
been reported in detail. The case fatality reported for
patients with COVID-19 shows large variability. Studies
have reported mortality ranging from 2% to 50%.3 17 The
discrepancies in mortality might arise from differences
in age groups affected, the testing capacity and whether
there were massive screenings.18 Also, in a systematic
review of 52 studies, the majority from China, median
length of hospital stay ranged from 4 to 53 days within
China and 4 to 21 days outside of China.19
In Pakistan, a significant number of critically ill
patients are admitted to intermediate or special care
units (SCU) due to a shortage of intensive care unit
beds.20 However, there is no empirical evidence of
favourable or unfavourable outcomes of patients
2

with COVID-19 admitted to various ALC, specifically
intermediate care units, from LMIC. Recognising the
correct ALC required for patients with COVID-19 and
determining their outcome is important, first because
patients in COVID-19 units are alone without family
members. Second, in settings with limited resources
patients who need high acuity care could be cared for
in intermediate care units with more vigilance and
gain favourable outcome compared with not finding
high acuity care at all. Third, the cost is an additional
important factor. In LMIC such as Pakistan, patients
are paying out of their pocket and high acuity care is
more expensive than lower levels of ALC. We hypothesise that recognising the correct level of acuity at
the time of admission for COVID-19-positive patients
in LMIC such as Pakistan is linked to their outcome
effective approach to
as this might be a more cost-
delivering care with limited resources. We, therefore,
aim to determine if ALC is a predictor of case fatality
and length of hospital stay in patients admitted with
COVID-19.
METHODS
We conducted an observational follow-up study at the
Aga Khan University Hospital (AKUH) from 26 February
2020 (index case in Pakistan) to 30 June 2020. All cases of
COVID-19 admitted according to ALC (low, intermediate
or high) during this period were followed up for case
fatality and length of hospital stay. A total of 822 adult
patients included (aged older than >18 years) with positive reverse transcription polymerase chain reaction for
COVID-19 were admitted from the emergency room or
through clinics to the COVID-19 diagnostic and testing
zone of the hospital. Patients admitted to services other
than internal medicine (eg, surgical or obstetrics due
to urgent surgical needs for preoperative screening for
COVID-19) were excluded (n=123) and 699 patients were
categorised into low, intermediate or high acuity care
level.
ALC was categorised as low, intermediate or high
level according to CDC, USA, for management of
COVID-19.16 Low acuity level care or general ward
care is defined as a dedicated ward for patients with
COVID-19 who require hospital care or oxygen administration but do not have severe disease. Oxygen
administration via nasal cannula/mask of maximum 4
L/min with intermittent monitoring of oxygen saturation and breathing frequency 3–4 times per day, intermediate care or SCU are defined as units dedicated for
patients who require oxygen therapy and continuous
monitoring of vital parameters (at least SpO2, ideally
blood pressure, heart rate and respiratory rate).
Oxygen administration is done via nasal cannula/
probe, venturi mask or reservoir mask. In ideal circumstances, the use of high-flow oxygen therapy and non-
invasive ventilation (NIV) is not recommended in
general or outside of an intensive care unit due to the
Almas A, et al. BMJ Open 2021;11:e045414. doi:10.1136/bmjopen-2020-045414
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Table 1 Characteristics of the three levels of acuity at the Aga Khan University Hospital
Characteristics of care

Low-level acuity

Intermediate-level acuity

High-level acuity

Emergency severity illness score

Stable patients* (P3)

Vitals monitoring

Every 6 hours

Unstable and critical patient†
(P2)
Continuous monitoring

Critical and life-threatening
patient (P1)
Continuous monitoring

Nurse-to-patient ratio

1:5

1:3–4

1:1

Doctor-to-patient ratio

1:8

1:4

1:3

Non-invasive ventilation available

No

Yes

Yes

Invasive ventilation available
Cost in US$/day

No
154

No
193

Yes
290

*Requiring hospital admission or oxygen.
†If unstable patients remain critical in the emergency room, they were initially admitted to high acuity.

risk of aerosols and of rapid deterioration in the case
of system failure.21 However, in the intermediate care
unit in the AKUH, NIV is used in intermediate care
beds as there is a limited capacity of Intensive care unit
(ICU) beds. Intensive or high acuity care is dedicated
to patients who have increasing organ dysfunction
(eg, increasing respiratory failure) or require invasive
ventilation or 1:1 nursing. Table 1 demonstrates the
specification of the three ALC.
The decision of placing the patients into the different
ALC was based on the standard ESI.15 According to
the triage process, patients with systolic blood pressure <100 mm Hg, or diastolic blood pressure <60 mm
Hg, or heart rate >100 beats per minute, or oxygen
saturation <92%, or who had altered mental status,
or had respiratory rate >24 breaths per minute were
considered as unstable and were admitted to intermediate acuity level. If unstable patients required invasive ventilation or invasive haemodynamic monitoring,
they were admitted to high acuity care. However,
when high acuity care beds were not available, those
patients who were impending invasive ventilation (on
more than 8 L oxygen and required continuous NIV)
or required limited haemodynamic monitoring (only
central venous pressure monitoring) were admitted
to intermediate care units instead. The outcome of
case fatality and length of stay were extracted through
the hospital information management system and the
COVID-19 diagnostic and testing zone daily log.
Age, sex and comorbidity of hypertension, diabetes,
ischaemic heart disease and chronic lung disease
(asthma and chronic obstructive lung disease) were
recorded and considered as confounders. Data on
patients who required invasive ventilation during
inpatient stay (which required shifting to high-level
acuity) were recorded. The data were extracted from
the daily automated admission log of the COVID-19
diagnostic and testing zone which was maintained by
head nurses of the respective units. Additionally, for
related code
validation of the data, the COVID-19-
07982 was extracted from the hospital information
and management system based on the International
Almas A, et al. BMJ Open 2021;11:e045414. doi:10.1136/bmjopen-2020-045414

Classification of Disease-9 coding (ICD-9), as well as
data on comorbid conditions: hypertension (ICD-9:
4019), diabetes (25000–25093), ischaemic heart
disease (41001–41091), asthma (49390–49392) and
chronic obstructive lung disease (49121), ventilation
(96.71 and 96.72).
Analysis
For the descriptive statistics, the mean (SD) or median
(IQR) as appropriate was used for continuous variables
and frequency and percentages for categorical variables.
The χ2 test, analysis of variance and Kruskal-Wallis test
were used as appropriate to compare the three levels of
acuity and a p value of <0.05 was considered statistically
significant. The ALC on admission was considered for
ascertaining the level of acuity. If there was a change in
acuity level, only the acuity level on admission was considered. The case fatality ratio (CFR), that is, the proportion of individuals diagnosed with COVID-19 concerning
those who died of COVID-19 was used as a measure of
severity among detected cases (CFR=Number of deaths
from COVID-19/number of confirmed cases of COVID-19
disease×100).22 Time-
to-
event (death) analysis was
performed using Cox regression. Endpoints considered
were time of fatality, end of inpatient stay or end of the
study period. Time to event was calculated in days, that is,
number of days from admission date to date of in-hospital
death, discharge or end of the study period. Models were
constructed for the association of acuity level, adjusting
for age and sex in model 1, and further adjustment for
comorbid conditions in model 2. Linear regression was
used to determine the association between acuity with
a length of stay using a similar modelling strategy HR
and beta coefficients with corresponding 95% CIs were
reported. Statistical package for social sciences V.22 was
used for all analyses.

RESULTS
Characteristics of the patients with COVID-19 are shown
in table 2. The mean age was 54.5 years and 67% were
males. A quarter of the patients were in the age range
3
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Table 2 Characteristics of patients with COVID-19, overall and according to the level of acuity (N=699)
Acuity care level

Mean (SD) age

Low

Intermediate

High

Overall

n=352 (50.4%)

n=297 (42.5%)

n=50 (7.2%)

N (%)

n (%)

n (%)

54.5 (15.4)

50.7 (16)

P value

59 (14)

56 (11)

<0.001

Age group (in years)
 18–30

60 (8.6)

48 (13.6)

11 (3.7)

1 (2)

 31–40

76 (10.9)

49 (13.9))

22 (7.4)

5 (10)

 41–50

128 (18.3)

76 (21.6)

42 (14.1)

10 (20)

 51–60

178 (25.5)

78 (22.2)

84 (28.3)

16 (32)

 61–70

151 (21.6)

61 (17.3)

77 (25)

13 (26)

 >70

106 (15.2)

40 (11.4)

61 (20.5)

5 (10)

 Male

473 (67.7)

233 (66.2)

204 (68.7)

36 (72)

 Female

226 (32.3)

119 (33.8)

93 (31.3)

14 (28)

0.6

 Diabetes

236 (33.8)

92 (26.1)

126 (42.4)

18 (36)

<0.001

 Hypertension

<0.001

Sex

Comorbidity
219 (31.3)

100 (28.4)

104 (35.0)

15 (30)

0.1

 Ischaemic heart disease

84 (12)

24 (6.8)

47 (15.8)

13 (26)

<0.001

 Chronic lung disease

39 (5.6)

19 (5.4)

18 (6.1)

2 (1)

0.8

159 (22.7)

18 (5.1)*

128 (43.1)

13(26)

<0.001

64 (9.2)

7 (2)†

28 (9.4)†

29 (58)

<0.001

26 (52)

<0.001

 Required non-Invasive ventilation
 Required invasive ventilation
 Case fatality ratio
 Mean length of stay (SD)
 Median length of stay (IQR)

81 (11.6)
7.26 (6.3)
6 (3–9)

7 (2)

48 (16.2)

5.3 (5.3)
4 (2–7)

8.3 (5.7)
7 (4–11)

14.2 (9.1)
12 (8–19)

<0.001
<0.001

*Shifted to higher care later or applied with palliative intent.
†Patients were moved to a high acuity level during their stay if they required invasive ventilation; the acuity level on admission was used in the
analysis.

51–60 years. Mean (SD) of the age of patients admitted
to intermediate care units was higher (59 (14) years)
than those admitted in low acuity care (50.7 (16) years)
or high acuity care (56 (11) years). Forty-five per cent of
the patients aged >60 years were admitted in intermediate
acuity care, followed by 36% in high acuity and 28% in
low acuity care. Diabetes was the most common comorbid
condition (34%) and 9.0% of patients required invasive
ventilation. Among comorbid conditions, more patients
with diabetes (42.4%) were admitted to intermediate
care and more patients with ischaemic heart disease were
admitted in high acuity care.
Acuity level of care
Most of the patients were admitted to low acuity care
(50.4%), followed by intermediate (42.5%) and 7.2% to
high acuity care. The patients requiring a higher level of
acuity (intermediate and high) were older than those in
low acuity care (table 2).
Figure 1 demonstrates the trend of patients admitted
with confirmed COVID-19 from 26 February to 30
June. There was a rise in admissions to low-
level and
intermediate-level acuity (28 to 179 in low acuity care and
4

7 to 136 in intermediate acuity care, respectively), while
the number of admissions in high-level acuity remained
similar throughout the period. Also, at least 17% of

Figure 1 The trend of monthly admissions of confirmed
patients with COVID-19 according to acuity level at Aga Khan
University Hospital internal medicine unit (N=699).
Almas A, et al. BMJ Open 2021;11:e045414. doi:10.1136/bmjopen-2020-045414
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Table 3 Effect of level of acuity cares on fatality in patients with COVID-19, HR and 95% CIs (N=699).
Multivariate
Univariate

Model 1*

Model 2†

HR (95% CI)

HR (95% CI)

HR (95% CI)

Acuity level of care
 Low

Ref

Ref

Ref

 Intermediate

4.6 (2.0 to 10.2)

3.4 (1.5 to 7.6)

2.7 (1.2 to 6.4)

 High

6.7 (2.8 to 15.9)

6.5 (2.7 to 15.5)

5.0 (2.0 to 12.1)

Age group (in years)
 18–30

Ref

 31–40

1.2 (0.2 to 6.5)

 41–50

0.5 (0.1 to 3.4)

 51–60

2.4 (0.5 to 10.6)

 61–70

2.2 (0.5 to 9.6)

 >70

5.0 (1.2 to 21.3)

Sex

0.9 (0.5 to 1.5)

Diabetes

1.9 (1.2 to 3.1)

Hypertension

0.8 (0.5 to 1.4)

Ischaemic heart disease

3.0 (1.9 to 4.8)

Chronic lung disease
Required invasive ventilation

0.8 (0.3 to 2.0)
2.6 (1.6 to 4.2)

*Adjusted for age and sex.
†Adjusted for age, sex and comorbidity including diabetes, hypertension, ischaemic heart disease and chronic lung disease.

patients fulfilled the criteria for being admitted to high
acuity care but were instead admitted to intermediate
care due to limited availability of high acuity beds. These
were mainly those who were impending invasive ventilation (on more than 8 L of oxygen and required continuous NIV) or who needed limited invasive central venous
pressure monitoring.
Case fatality
Overall CFR was 11.6%. Comparing the case fatality
between the three ALC showed that it was highest in the
high acuity level patients (52%), followed by intermediate acuity level patients (16.2%) and 2% among low
acuity care patients (table 2). Out of the 17% patients
(141) who required high acuity care but were admitted to
intermediate acuity care mentioned above, 71% (n=100)
survived and 29% (n=41) succumbed to death by the end
of the inpatient stay. In the univariate analysis, the HR
(95% CI) was 6.7 (95% CI 2.8 to 15.9) for high acuity
and 4.6 (95% CI 2.0 to 10.2) for intermediate acuity care
compared with low acuity care. Among the covariates,
age >70 years (HR=5.0), diabetes (HR=1.9), ischaemic
heart disease (HR 3.0) and requiring invasive ventilation
(HR=2.6) were associated with fatality. In the multivariate
analysis after adjusting for age and sex, increased risk for
death remained for intermediate acuity (HR 3.4) and
high acuity care (HR 6.5) and after further adjustment
of comorbidity in the final model (table 3). The monthly
Almas A, et al. BMJ Open 2021;11:e045414. doi:10.1136/bmjopen-2020-045414

trend of CFR is shown in figure 2. For subgroup analyses
of low ALC with mortality, the HR (95% CI) was 0.30
(95% CI 0.1 to 0.6) after adjusting for age, sex and comorbidities including diabetes, hypertension, ischaemic heart
disease and chronic lung disease. There was no association of comorbidities with mortality in those admitted
to low acuity care (p value 0.05 for chronic lung disease,
p value 0.4 for hypertension, p value 0.07 for ischaemic
heart disease and p value 0.2 for diabetes).

Figure 2 The trend of case fatality ratio of patients with
COVID-19 according to acuity level at Aga Khan University
Hospital internal medicine unit (N=699).
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Table 4 Effect of level of acuity on length of stay in patients with COVID-19, beta coefficients with corresponding 95% CI
(N=699)
Multivariate

Acuity level of care
 Low

Univariate

Model 1*

Model 2†

Beta (95% CI)

Beta (95% CI)

Beta (95% CI)

Ref

Ref

 Intermediate

2.9 (2.0 to 3.8)

2.7 (1.8 to 3.7)

2.9 (1.9 to 3.8)

 High

8.8 (7.1 to 10.5)

8.7 (6.9 to 10.4)

8.9 (7.1 to 10.6)

Age (in years)
Sex
Diabetes

Ref

0.04 (0.01 to 0.07)
0.7 (-0.2 to 1.7)
0.06 (0.4 to 2.4)

Hypertension

1.4 (0.4 to 2.4)

Ischaemic heart disease

1.4 (−0.006 to 2.8)

Chronic lung disease
Required invasive ventilation

1.4 (−0.6 to 3.4)
7.0 (5.4 to 8.5)

*Adjusted for age and sex.
†Adjusted for age, sex and comorbidity including diabetes, hypertension, ischaemic heart disease and chronic lung disease.

Length of hospital stay
The overall average length of stay in the hospital was 7.26
days (table 1). The overall median (IQR) was 6 (IQR
3–9) days. Comparing the three acuity levels, it was the
longest for high-
level acuity (14.2 days). In univariate
analysis, the beta coefficient (95 % CI) was 8.8 (95% CI
7.1 to 10.5) for high acuity and 2.9 (95% CI 2.0 to 3.8) for
intermediate care. Among the covariates only requiring
invasive ventilation was associated with prolonged length
of stay (beta 7.0 (5.4, 8.5)). In the multivariate analysis
of acuity level with a length of stay, the association was
increased for intermediate acuity (beta 2.7 (95% CI 1.8
to 3.7)) and high acuity care (beta 8.7 (95% CI 6.9 to
10.4)) after adjustment for age and sex. The association
remained also after considering comorbidity (table 4).
The monthly trend of an average length of stay among
different acuity levels is shown in figure 3. On average,
there was a 1-day reduction in overall length of stay from

Figure 3 The average length of stay of patients with
COVID-19 according to acuity level at Aga Khan University
Hospital internal medicine unit (N=699).

6

February to June and a 1-day reduction in length of stay
in intermediate care.
DISCUSSION
In this study, we found that the case fatality of patients
with COVID-19 in our setting was highest in the high
acuity care followed by intermediate care and low acuity
care. The outcome was favourable (lower case fatality) of
critical patients admitted to intermediate care compared
with high acuity care as high acuity care beds are limited.
This association was independent of age, sex and high-
risk comorbid conditions including diabetes, hypertension, ischaemic heart disease and chronic lung disease.
This supports the fact that the severity of the disease at
the time of admission and triage into the respective care
level is a strong predictor of case fatality in this patient
population. A similar association was found for the length
of hospital stay. The study signifies the importance of
initial triaging of patients with COVID-19 into appropriate acuity levels as a predictor of outcome.
The comparable CFR in the intermediate care units
implies that most patients were well managed and were
able to reduce the need for high acuity care in such a
resource-limited situation.23 A meta-analysis of 10 clinical
studies from China on 1995 cases of COVID-19 reported
a CFR of 5%.24 Mortality in COVID-19 patients has also
been reported as high as 28%–30% from different regions
including China and the USA.17 25 At the beginning of the
pandemic, several European countries reported higher
mortality of the initially diagnosed cases, up to 25.6%,26
and several prognostic factors were highly associated with
mortality, for example, older age and other prognostic
scores such as sequential organ failure assesment, CURB6526 or Pneumonia Severity Index,27 which could help
Almas A, et al. BMJ Open 2021;11:e045414. doi:10.1136/bmjopen-2020-045414
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improve the prognosis value of the ALC at triage as they
are easy and quick to calculate. Across European countries,
the CFR has been reported to be around 5%–20%.28–31
Case fatality varies depending on the population source.29
According to the official government portal of Pakistan
capturing population-
based data, the overall mortality
for COVID-19 in Pakistan was 2.1% and in Sindh (the
southern province in which Karachi is located) was 1.8%.5
In this study, the overall case fatality from hospital-based
data was 11%, which is comparable and even lower than
the mortality reported from hospitals of upper-middle-
income countries. CFR from hospital settings in India,
a neighbouring country with a similar genetic, ethnic
and cultural background, was reported to be 28%.32 The
reason for the variation in case fatality across the globe
might be linked to underdetection of mild or asymptomatic cases or differences in medical care.33 Of note,
changes in the management of COVID-19 over time with
steroids and other trial drugs such as remdesivir and
tocilizumab might have also impacted case fatality over
time.34 35 Additionally, our centre is a tertiary care centre
and the first one to treat patients with COVID-19 in Pakistan, hence a significant number of patients presented
with moderate-to-severe disease due to delayed presentation from within and outside Karachi. Other mechanisms
including genetics, immunity and environmental factors
need further exploration.
While many studies report the outcomes of COVID-19
based on the severity of the disease, comparatively fewer
studies present the CFR among the different ALC of
patients at admission. In a study from Italy on 174 non-
critical COVID-19 patients, the CFR reported was 2.5%.29
This is identical to our rate for those who were initially
admitted to low acuity care. Although high-flow oxygen
therapy and NIV are not recommended in general and
outside of an intensive care unit.21 NIV support techniques
have been used to develop a respiratory intermediate care
unit to implement non-invasive oxygenation in France.36
NIV is beneficial in the initial management of acute respiratory distress syndrome associated with SARS-
CoV-2,
particularly in times of ICU shortage. The same strategy
was used in our intermediate care units by using NIV and
hence preventing early intubation where justified. Data
from an observational study on 670 consecutive patients
with confirmed COVID-19, managed in an out-of-ICU
setting, in nine hospitals showed an unadjusted mortality
rate of 26.9%; the patients in these units were managed
with high-flow nasal cannula, NIV or continuous positive
airway pressure.37 The CFR from our intermediate care
unit was 16%, thus lower than reported in the former
study. The reason for this could be that our medical staff
was accustomed to managing patients on NIV in a respiratory unit even before the COVID-19 pandemic, hence
they might be more skilled in managing acute respiratory
distress syndrome and hypoxia.38 Second, due to resource
limitations in intubation of patients, we might have used
NIV for longer periods or maintained a higher threshold
for intubation. Third, our respiratory units for patients
Almas A, et al. BMJ Open 2021;11:e045414. doi:10.1136/bmjopen-2020-045414

with COVID-19 were primarily managed by an internist
and pulmonologist who were involved in consultations.
As internists have experience in managing patients with
multimorbidity and have a holistic approach in managing
patients, this might have improved the overall outcome of
these patients. For example, patients with COVID-19 are
more likely to have uncontrolled diabetes and for better
outcomes good glycaemic control is essential.39 A meta-
analysis on 14 studies on 4659 patients reported diabetes
and ischaemic heart disease as predictors of mortality in
patients with COVID-19 in addition to other inflammatory and clinical parameters.40 In another meta-analysis of
6452 patients from 30 studies, diabetes mellitus doubled
the risk of mortality in patients with COVID-19 and so did
ischaemic heart disease.41 42 In the current study, having
diabetes or ischaemic heart disease was associated with
increased fatality. Hence, our findings are in alignment
with the former research findings.
For patients admitted to ICUs, the case fatality had been
reported to be around 40%–50% in the USA.43 44 Data
from six COVID-designated ICUs from Atlanta, Georgia,
USA, (n=217) demonstrated mortality of 35.7%.45
Our CFR is 50% which is comparable to what has been
reported from other regions. This relatively higher case
fatality could be due to severe disease and delayed presentation to the hospital due to limited critical care facilities
in the city. Second, it might also be linked to the different
South Asian backgrounds of the patient population.46 In
contrast, mortality rates reported from Washington, USA,
(n=21) were as high as 67%.47 It is useful to note here that
despite being an LMIC the care provided to patients with
COVID-19 was comparable to that provided in certain
high-
income countries. There is an urgent need for
collaborative efforts of ICU practitioners, hospital administrators, governments and policy-makers to prepare for
a substantial increase in critical care bed capacity, with
a focus on infrastructure, supplies and staff management.23 The Sindh government is collaborating with the
AKUH to provide free training and technical assistance to
healthcare professionals working in the public sector in
providing critical care to patients with COVID-19.48
Addressing CFR according to age indicates that it
ranges from 3.5% to 20% among those aged >60 years in
Italy and 3.6%–14% in the same age range in China.29 49
Our CFR shows the same trend of being higher in those
aged >than 60 years. However, these CFR figures might be
overestimated as our data are based on clinical data and
are not population based. The higher CFR in the older
population might also be because they were not subjected
to invasive ventilation due to poorly predicted outcomes
associated with old age, frailty, comorbidities or logistic
limitations due to the non-availability of ventilated beds.18
Also, the risk of having a critical disease is higher in individuals having age above 50 years or those having comorbidities, hence requiring higher ALC. This might be one
reason that more elderly population was admitted in
intermediate acuity level rather than low or high acuity
level in this study.
7

BMJ Open: first published as 10.1136/bmjopen-2020-045414 on 28 May 2021. Downloaded from http://bmjopen.bmj.com/ on June 9, 2021 at Aga Khan University. Protected by copyright.

Open access

Regarding the length of hospital stays due in patients
with COVID-19, a systematic review of 52 studies reported
a median length of hospital stay ranging from 4 to 53 days
in China and 4 to 21 days outside of China.19 For an ICU
stay, it was 14 days within China and 7 days (4–11) outside
China. The review further stated that the length of stay
was longer for those who survived versus those who did
not survive. Our overall median length of stay was 6 days
with an IQR of 3–9 days, which is significantly lower than
what is reported from China, although the median ICU
stay was similar, 12 (IQR 8–19), and similar to ICU stays
elsewhere. A potential reason for a considerably lower
median stay in non-critical patients might be that the
pandemic lagged behind in countries outside of China,
which might have provided ample opportunity for these
countries to use trial drugs including steroids, tocilizumab and remdesivir which potentially contributed to
improved outcomes.50–52
The strength of our study is that it is the first of its kind
to report the association between ALC of patients with
COVID-19 and CFR from a hospital in an LMIC. This centre
is the pioneer hospital in a city of 17 million people that
started treating critical patients with COVID-19, hence the
results do have implications as a guidance for other hospitals that treat patients with COVID-19. The study was able
to adjust not only for the bias of confounding by sex and
age but also for important comorbidities. Nonetheless,
there are several limitations to the study. This is a single-
centre study; hence, the results are not generalisable to
the entire population. Also, the severity of patients based
on radiological and laboratory parameters has not been
reported in this study as we relied on data regarding acuity
level. Also, only a limited number of common comorbid
conditions were investigated and compared across acuity
levels and mortality; expanded clinical datasets would be
beneficial to investigate for further research. We also did
not report data on different drugs that were used in the
treatment of COVID-19.

CONCLUSION
High and intermediate acuity levels are associated with
higher CFRs and prolonged length of hospital stay in
patients with COVID-19 compared with patients admitted
to low acuity levels. In resource-limited settings where the
provision of high acuity care is limited, the intermediate
care acuity could serve as a useful strategy to treat relatively less critical patients with COVID-19. It is important
to accurately triage patients with COVID-19 based on the
level of care as improvements in clinical outcomes and
overall survival depends on it. In LMIC such as Pakistan, government and private sector hospitals can aim
to develop more intermediate care units in addition to
intensive care units for useful and cost-effective care of
patients.
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